Laboratory Corporation of America Holdings (NYSE: LH) is -24.16% lower on its value in year-to-date trading and has touched a low of $200.32 and a high of $317.17 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LH stock was last observed hovering at around $236.75 in the last trading session, with the day’s gains setting it 1.54% off its average median price target of $275.00 for the next 12 months. It is also 24.35% off the consensus price target high of $315.00 offered by 17 analysts, but current levels are 4.68% higher than the price target low of $250.00 for the same period.
Currently trading at $238.29, the stock is 2.41% and 7.92% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.47 million and changing 0.65% at the moment leaves the stock -2.55% off its SMA200. LH registered -16.66% loss for a year compared to 6-month loss of -3.68%.
The stock witnessed a 4.42% gain in the last 1 month and extending the period to 3 months gives it a 0.52%, and is -2.26% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.30% over the week and 3.05% over the month.
Laboratory Corporation of America Holdings (LH) has around 75500 employees, a market worth around $21.37B and $15.26B in sales. Current P/E ratio is 12.72 and Fwd P/E is 13.51. Profit margin for the company is 11.50%. Distance from 52-week low is 18.95% and -24.87% from its 52-week high. The company has generated returns on investments over the last 12 months (15.90%).
Laboratory Corporation of America Holdings (LH) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Laboratory Corporation of America Holdings (LH) is a “Buy”. 17 analysts offering their recommendations for the stock have an average rating of 1.90, where 3 rate it as a Hold and 2 think it is a “Overweight”. 12 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Laboratory Corporation of America Holdings is expected to release its quarterly report on 02/09/2023.The EPS is expected to grow by 53.60% this year
Laboratory Corporation of America Holdings (LH) Top Institutional Holders
The shares outstanding are 90.20M, and float is at 88.36M with Short Float at 1.30%.
Laboratory Corporation of America Holdings (LH) Insider Activity
A total of 24 insider transactions have happened at Laboratory Corporation of America Holdings (LH) in the last six months, with sales accounting for 14 and purchases happening 10 times. The most recent transaction is an insider sale by Schroeder Mark S, the company’s EVP, President-Diagnostics Lab. SEC filings show that Schroeder Mark S sold 1,116 shares of the company’s common stock on Nov 08 at a price of $232.67 per share for a total of $0.26 million. Following the sale, the insider now owns 6687.0 shares.
Laboratory Corporation of America Holdings disclosed in a document filed with the SEC on Sep 26 that EISENBERG GLENN A (Chief Financial Officer, EVP) sold a total of 25,000 shares of the company’s common stock. The trade occurred on Sep 26 and was made at $210.62 per share for $5.27 million. Following the transaction, the insider now directly holds 27158.0 shares of the LH stock.
Still, SEC filings show that on Sep 07, Caveney Brian J (EVP, President of Diagnostics) acquired 44 shares at an average price of $231.20 for $10251.0. The insider now directly holds 14,282 shares of Laboratory Corporation of America Holdings (LH).
Laboratory Corporation of America Holdings (LH): Who are the competitors?
The company’s main competitors (and peers) include IQVIA Holdings Inc. (IQV) that is trading -17.93% down over the past 12 months and Centene Corporation (CNC) that is 10.00% higher over the same period. Enerplus Corporation (ERF) is 74.98% up on the 1-year trading charts.